Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

Once-daily orforglipron helps preserve weight loss after semaglutide or tirzepatide

Oral orforglipron helped adults maintain clinically meaningful weight loss after prior injectable tirzepatide or semaglutide therapy. The phase 3b ATTAIN-MAINTAIN trial suggests switching to once-daily oral therapy may help reduce weight regain when injectable treatment is discontinued.

13 May 2026

Perimenopausal women face higher risk of low heart health

Perimenopausal women were two times more likely to have a low cardiovascular health score compared to women having regular menstrual cycles, according to an analysis of nationwide U.S. data published today in the Journal of the American Heart Association, an open-access, peer-reviewed journal of the American Heart Association.

13 May 2026

Large human islet study reveals new insights into diabetes risk

Diabetes is the most common and serious chronic disease worldwide, characterized by insufficient insulin to maintain proper blood glucose levels.

12 May 2026

Could GLP-1 drugs help breast cancer patients live longer?

A large retrospective cohort study of adult female breast cancer patients found that GLP-1 receptor agonist use was associated with better all-cause survival and recurrence-free survival in patients with obesity or type 2 diabetes. The strongest associations were seen versus non-use in obesity and versus insulin or metformin in type 2 diabetes, while comparisons with SGLT2 inhibitors were less consistent and require further study.

12 May 2026

Maternal insulin resistance linked to higher abdominal fat in girls

Girls born to mothers with higher insulin resistance during the third trimester are more likely to have more abdominal fat at age 7, according to research presented at the 28th European Congress of Endocrinology in Prague.

12 May 2026

Cannabis compounds may improve metabolism and reduce diabetes risk

A University of California, Riverside preclinical study is shedding light on a long-observed but poorly understood phenomenon: chronic cannabis users tend to have lower body weight and a reduced risk of developing type 2 diabetes, despite the drug's well-known tendency to increase appetite.

11 May 2026

Why are so many mothers missing diabetes follow-up after childbirth?

A New York City cohort study found that few women with postpartum-onset diabetes received guideline-recommended A1C monitoring over three years. Non-Hispanic Black women and mothers with more children faced lower monitoring rates, while Medicaid coverage was linked to better follow-up.

11 May 2026

Partners of women with gestational diabetes face higher health risks

Partners of women with gestational diabetes have more health-related risk factors and morbidity than partners of women without gestational diabetes.

11 May 2026

Diabetes, weight-loss drugs not a perfect fit?

Type 2 diabetes affects millions of people worldwide and now a new international study, jointly led by Adelaide University, University of Oxford, ETH Zurich, and Stanford University, has found one in ten people may not be benefiting from common medications used to treat the condition.

11 May 2026

Urges for cardiologists to screen patients for UPF intake

The European Society of Cardiology identifies ultra-processed foods as a key cardiovascular risk, urging a shift in dietary guidelines for better heart health.

11 May 2026

Daily orforglipron treatment reduces weight and blood sugar in seniors

A new analysis to be presented at this year's European Congress on Obesity (ECO 2026, Istanbul, Turkey, 12-15 May) examined daily oral orforglipron treatment for the treatment of obesity, with or without diabetes, in users aged 65 years and over, with results and a safety profile similar to that seen in the ATTAIN clinical trial programme population.

11 May 2026

Heart disease risk increases in women with polycystic ovary syndrome

Heart disease risk has been found to increase in women with polycystic ovary syndrome (PCOS), even in those with normal weight, according to research presented at the 28th European Congress of Endocrinology in Prague.

10 May 2026

Greater weight loss from GLP-1 drugs lowers health complication risk

New research to be presented at this year's European Congress on Obesity (ECO 2026, Istanbul, Turkey, 12-15 May) shows that, following treatment for obesity or diabetes or both using incretin-based drugs, losing more weight versus less weight, and losing a little weight versus gaining weight, both lead to relatively lower risk of obesity-related conditions.

10 May 2026

Liver fat may disrupt post-meal glucagon control in early type 2 diabetes

Researchers found that MASLD, rather than type 2 diabetes alone, was linked to higher fasting glucagon levels in adults with newly diagnosed diabetes and matched controls. In people with early type 2 diabetes, higher liver fat was specifically associated with exaggerated early post-meal glucagon responses, independent of insulin sensitivity, visceral fat, amino acids, or NEFAs.

10 May 2026

Asthma medication formoterol shows promise for treating fatty liver disease

MUSC researchers are tackling MASH, or metabolic dysfunction-associated steatohepatitis, a liver disease affecting hundreds of millions worldwide.

8 May 2026

Insulin-dependent diabetes linked to sharply higher dementia risk

Individuals with diabetes are at an increased risk of developing dementia but those with insulin-requiring type 2 diabetes and type 1 diabetes have the greatest risk, according to research presented at the 28th European Congress of Endocrinology in Prague.

8 May 2026